<div id="readability-page-1">07:40 AM EST, 12/04/2025 (MT Newswires) -- uniQure (QURE) said Thursday that it will &#34;urgently&#34; seek a follow-up&#34; meeting with the US Food and Drug Administration after the regulator said phase 1/2 studies of AMT-130 data are now unlikely to support a Biologics License Application submission.AMT-130 is an investigational gene therapy intended to treat patients with Huntington's disease, the company said.uniQure said it is evaluating the feedback and is looking to meet with the FDA in Q1.Shares of uniQure were down 19% in recent Thursday premarket activity. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

QURE

uniQure 計劃在被告知 AMT-130 的 1/2 期研究數據不太可能支持生物製品許可申請後，緊急與美國 FDA 會面。AMT-130 是一種用於亨廷頓舞蹈症的基因療法。該公司旨在於第一季度與 FDA 會面。uniQure 的股票在盤前交易中下跌了 19%

Uniqure 在被告知數據不支持生物製品許可申請（BLA）提交後，尋求與美國食品藥品監督管理局（FDA）的後續會議